Lactobacillus Strain Composition for Prediabetes and Blood Glucose Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing probiotics do not effectively address metabolic health issues such as prediabetes, insulin resistance, high blood glucose, and gut barrier dysfunction, particularly in response to high-fat and high-sugar diets.
Innovation Solution
Development of Lactobacillus strains, specifically DSM 17648, DSM 32851, DSM 32853, DSM 32910, and DSM 32911, formulated in discrete dosage forms to improve metabolic health by reducing insulin resistance, lowering blood glucose levels, and enhancing gut barrier function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional probiotics are used, then general gut health may be improved, but they lack specific effectiveness for prediabetes and metabolic health issues
Solution Approach 1:
The patent segments the probiotic market by identifying and isolating specific Lactobacillus strains (L. casei subsp. casei DSM 32911, L. rhamnosus DSM 32910, L. paracasei subsp. paracasei DSM 32853) that demonstrate proven efficacy for metabolic health conditions. This segmentation allows targeted selection of strains with demonstrated ability to improve insulin sensitivity and blood glucose control, rather than using generic probiotic formulations.
Solution Approach 2:
The patent changes the selection criteria parameter from general probiotic properties to specific metabolic health outcomes. By selecting strains based on their demonstrated ability to improve insulin sensitivity, reduce blood glucose levels, and enhance gut barrier function, the formulation achieves specificity for prediabetes management while maintaining reliability through clinically validated strain selection.
2Reliability
If probiotic strains are selected for metabolic health benefits, then effectiveness for prediabetes is improved, but the composition becomes more specialized and less versatile for other conditions
Solution Approach 1:
The patent achieves universality by selecting Lactobacillus strains that simultaneously address multiple metabolic health parameters. The chosen strains demonstrate efficacy across several conditions including prediabetes, type 2 diabetes, metabolic syndrome, and obesity, making the formulation versatile for various metabolic disorders while maintaining specialized effectiveness for each condition through the same core strain combination.
3Manufacturing precision
If specific Lactobacillus strains are used for metabolic health, then blood glucose control is improved, but the formulation requires precise strain selection and formulation
Solution Approach 1:
The patent performs preliminary action by pre-selecting and validating specific Lactobacillus strains (DSM 32911, DSM 32910, DSM 32853) that have demonstrated efficacy for metabolic health before formulation. This pre-validation of strain selection simplifies the manufacturing process, as the precise strain combination is already optimized and validated, reducing the complexity of formulation development while maintaining manufacturing precision.
Data Source
AI summary
The application discloses Lactobacillus strains having a beneficial effect on the metabolic health on a mammalian subject. Further disclosed is compositions comprising such strains and the use thereof for improving the metabolic health or for lowering the blood glucose level in a mammalian subject.